A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease

@article{Choi2015AP2,
  title={A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease},
  author={J. Choi and B. Lee and J. M. Ko and Y. B. Sohn and Jin-Sung Lee and G. Kim and S. Heo and June-Young Park and Y. Kim and Ja-Hye Kim and Han-Wook Yoo},
  journal={Journal of Korean Medical Science},
  year={2015},
  volume={30},
  pages={378 - 384}
}
  • J. Choi, B. Lee, +8 authors Han-Wook Yoo
  • Published 2015
  • Medicine
  • Journal of Korean Medical Science
  • Gaucher disease is a lysosomal storage disease for which enzyme replacement therapy has proven to be effective. A switch-over clinical trial was performed to evaluate the efficacy and safety of Abcertin® (ISU Abxis, Seoul, Korea) in subjects with type 1 Gaucher disease who were previously treated with imiglucerase. Five Korean patients with type 1 Gaucher disease were enrolled. Previous doses of imiglucerase ranged from 30 to 55 U/kg every other week. The same dose of Abcertin® was administered… CONTINUE READING
    8 Citations

    Figures, Tables, and Topics from this paper

    References

    SHOWING 1-10 OF 27 REFERENCES
    Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study
    • 50
    Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
    • 80
    • PDF
    The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    • 106
    The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    • 85
    • PDF
    Replacement therapy with imiglucerase for type 1 Gaucher's disease
    • 101
    Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    • 1,081